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CObjectives: The purpose of our study was to use health-related quality of
life data from the Women’s Health Initiative to calculate health-related
utility weights and examine differences in these health utility weights
across different hemoglobin (Hgb) levels. These utility weights could then
be used in future cost-effectiveness studies. Methods: Health utility
eights were measured by the Short Form-6D (SF-6D), a health utility
ndex derived from the Short Form Medical Outcomes questionnaire.
djusted least square means were calculated for each level of Hgb at
aseline and in longitudinal regression analysis the relationship be-
ween change in Hgb and change in the SF-6D was examined. Both
aseline and longitudinal analyses were performed for all postmeno-
ausal women and separately for those with self-reported heart fail- O
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doi:10.1016/j.jval.2010.11.008re, cancer, and osteoarthritis. Results: Women with Hgb in the anemic
ange had lower health utility weights than those with higher Hgb levels.
ongitudinally, a loss of of 2 g/dl Hgb or more was associated with a sta-
istically significant and clinically meaningfully decline in SF-6D in all
articipants and also in the group of participants with cancer and osteo-
rthritis, but not in those with heart failure.Conclusions: Lower levels of
gb and a loss of Hgb are associated with a statistically significant and
linically meaningful decrement in health utility in all postmenopausal
omen we studied and also in those with chronic conditions.
eywords: health utilities, hgb, osteoarthritis, postmenopausal.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The economic impact of blood loss leading to anemia can be con-
siderable. A recent study examined the cost differences between
patients with and without anemia in six different chronic dis-
eases: heart failure (HF), rheumatoid arthritis, inflammatory
bowel disease, chronic obstructive pulmonary disease, chronic
kidney disease, and cancer [1]. After adjusting for comorbiditiy
and disease severity they found patients with anemia incurred
excess annual costs that ranged from $7000 in rheumatoid arthri-
tis to $29,000 in patients with congestive HF.
Anemia occurs when a person’s blood does not have enough
hemoglobin (Hgb). Hgb is a protein in red blood cells that carries
oxygen from lungs to the rest of the body. The World Health Or-
ganization has classified for women a Hgb level less than 12 g/dl as
anemia [2]. A decrease in Hgb more than 2 g/dl from baseline has
been considered to be clinically important blood loss [3]. Among
women with a Hgb level lower than 14 g/dl at baseline, the 2 g/dl
Hgb decrease would have resulted in the World Health Organiza-
tion-defined anemia. For women who are anemic at baseline, the
2 g/dl Hgb decrease would have led to even more serious anemia.
Hgb levels reflect a steady state between both the rate of produc-
tion of red blood cells, rate of destruction, and chronic blood loss.
Although certain chronic diseases are known to be associated with
* Address correspondence to: Brooke Harrow, PhD, Medical Affairs
MA 02139-4242, USA.
E-mail address: Brooke_Harrow@vrtx.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.perturbations in this dynamic process, in some cases the treatment
of these chronic diseases leads to alterations in Hgb levels. For exam-
ple, nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly
prescribed for osteoarthritis and have been associated with gastro-
intestinal toxicity-associated blood loss [4].
Blood loss has both economic and quality of life (QoL) implica-
tions. Therefore when considering the trade-offs between the bene-
fits of medical therapy versus its negative side effects for a specific
disease, understanding the effects of these therapies on Hgb levels
and its attendant effects on both the costs and QoL is important.
Indeed, health techonology assessment groups and reimbursement
authorities consider the cost per quality-adjusted life years when
making reimbursement decisions for drugs and medical devices.
Recent work on the measurement of health utility for anemia-
related health states has been limited to patients with anemia asso-
ciated with cancer treatment [5], treatment for hepatitis C [6,7] or
enal failure [8]. The Center for the Evaluation of Value and Risk in
ealth, at Tufts University’s Cost-Effectiveness Analysis Registry has
ncluded utility weights for different Hgb levels from eight studies
6–13]. None of these studies has looked at QoL or utility weights
elated to Hgb levels in a healthy population. The assignment of util-
ty weights to Hgb levels in a larger population can provide an excel-
ent source for future studies of the cost-effectiveness of interven-
ions developed to mitigate blood loss and perhaps prevent anemia.
arch, Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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556 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 5 5 – 5 6 3The purpose of our study was to use health-related QoL data from
the Women’s Health Initiative (WHI) to calculate health utility
weights and examine differences in these health utility weights
across different Hgb levels. Given the lack of information on how
clinically important blood loss affects patients’ QoL, our study also
assessed the relationship between the loss in Hgb and the change in
health utility. The WHI study includes a large cohort of postmeno-
pausal women that has high quality data on the Short Form Medical
Outcomes questionnaire (SF-36), as well as recordings of Hgb levels.
These data are an ideal source to address the questions:
● What are the utility weights for varying levels of Hgb adjusted
for confounding factors in postmenopausal women? That is, do
women with anemia have lower health utilities?
● What is the relationship between the loss in Hgb and the
change in health utility over time? That is, do women who lose
2 g Hgb or more over 3 years have worse health utilities com-
pared to women whose Hgb level did not drop?
Methods
Study population
The WHI is a national study that recruited women through 40 US
clinical sites during 1993–1998 [14,15]. Study participants were
omen aged 50 to 79 years at baseline. Women were excluded if they
id not plan to reside in the area of the study clinic for at least 3 years,
ad medical conditions predictive of less than 3 years of survival, or
Fig. 1 – Adjusted* baseline Short Form-6D utility weights by
participants in the Women’s Health Initiative study. *Data fo
ethnicity, education level, body mass index, exercise level, d
reported history of disability, bleeding problems, intestine r
disease, diabetes, lupus (not on treatment), stroke or heart a
failure, and osteoarthritis. In patients with osteoarthritis (OA
except excluding osteoarthritis. In patients with heart failur
subjects, except excluding HF. In patients with cancer adjus
excluding cancer. For patients int the healthy cohort adjuste
excluding liver disease, diabetes, lupus (not on treatment), s
cancer, heart failure, and osteoarthritis.had complicating conditions such as alcoholism, mental illness, or
dementia. Those eligible for either the clincal trial or observational
arms completed baseline assessments, including a complete blood
count, clinical exam, medication inventory, questionnaires including
self-reported diseases and SF-36 questionnaires. A standardized
written protocol, centralized training of local clinical staff, local qual-
ity control, and periodic quality assurance visits by the clinical coor-
dinating center were used to maintain uniform data collection pro-
cedures at all study sites. Reproducibility of WHI questionaire data
was evaluated in a random subsample at 10 weeks with good to
excellent reproducibility (weighted  0.77 to 0.99) [14].
For the longitudinal analysis, participants in the observational
tudy or those in the control arms of the randomized trials were
onsidered as the basis for the follow-up sample. In addition, the
ligible participants needed to complete the 3-year follow-up visit
uestionnaires and provide a blood sample for analysis. Women in
he treatment arms of the randomized trials were excluded from
he follow-up analysis due to concern for potential influence on
reatment on Hgb level and/or ultility weights at the 3-year fol-
ow-up assessment.
Measures
Hemoglobin levels
A complete blood count was drawn and analyzed by certified lab-
oratories at each of the 40 clinical sites. Baseline Hgb levels and
change in Hgb levels over a 3-year period were obtained.
oglobin (Hgb) level in postmenopausal women
subjects was adjusted for baseline Hgb group, age, race/
ssion, randomized controlled trial status, and self-
val, any overnight hospitalizations in prior 2 y, liver
, rheumatoid arthritis (not on treatment), cancer, heart
justed variables were the same as those for all subjects,
) adjusted variables were the same as those for all
ariables were the same as those for all subjects, except
riables were the same as those for all subjects, exept
e or heart attack, rheumatoid arthritis (not on treatment),hem
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epre
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The SF-6D is a health utility index derived from the SF-36 health-related
QoL. The SF-6D has six dimensions: physical functioning, role limita-
tions, social functioning, pain, mental health, and vitality. Each dimen-
sion has between two and six levels. More than 18,000 health states
have been classified using the SF-6D [16]. The SF-6D algorithm esti-
mates a preference-based measure of health from the responses ob-
tained in the SF-36. SF-6D values range between zero (indicating death)
and one (indicating excellent health). The SF-6D preference weights
were derived from a sample of the general population using the valua-
tion technique of standard gamble. The advantage of using the SF-6D
rather than using the SF-36 is that the SF-6D weights allow for calcula-
Fig. 2 – Women’s Health Initiative (WHI) study sample selec
disease; OS, osteoarthritis; RCT, randomized controlled trialtion of quality-adjusted life years that can be used to compare the rela-tive merits (cost-effectiveness) of different types of interventions. A dif-
ference of 0.025 in the SF-6D has been judged to be a the minimal
clinically important difference (MICD) in QoL for this index [17].
Covariates
Sociodemographic factors (age, race/ethnicity, and education) were
asked at baseline. Disability status was based on a response to current
job status as “disabled, unable to work.” Physical activity was quantified
as a continous variable in metabolic equivalents per week using a vali-
datedquestionaireandpublisheddatabaseofphysicalactivityandmet-
abolic equivalent intensities. Baseline depressive symptoms were as-
sessed by self-report using Burnam’s eight-item scale for depressive
disorders (major depression and dysthymia) [18,19]. The distribution of
diagram. RA, rheumatoid arthritis; CKD, chronic kidneytion
.scores was highly skewed, suggesting a binomial distribution. There-
●558 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 5 5 – 5 6 3fore, as has been done in other studies, a cutpoint of 0.06 of higher was
used to dichotomize the continuous score.
Several comorbidities were assessed:
● The presence of cardiovascular disease was based on an affir-
mative answer to one of the following questions: “Did a doctor
ever say that you had a stroke?” or, “Did a doctor every say that
you had a heart attack?”
● The identification of liver disease was based on an affirmative
answer to the following question: “Did a doctor ever say that you
had any of the following health problems? Liver disease (chronic
active hepatitis, cirrhosis, or yellow jaundice)?”
● Women with diabetes were identified based on the question,
“Did a doctor ever say that you had diabetes or high blood sugar
when you were not pregnant?”
● Gastrointestinal surgery history was determined based on an af-
firmative answer to the following question: “Has a doctor told you
that you have any of the following conditions or have you had any
of the following procedures . . . Part of intestines taken out.”
● Women were identified as having osteoarthritis, HF, or can-
cer based on the following questions: osteoarthritis was
identified by an affirmative response to the question, “Did
your doctor ever say that you had arthritis?” coupled with
any response other than “rheumatoid arthritis” to the fol-
low-up question, “What type of arthritis do you have?”
* The presence of HF was determined by an affirmative response
to the question, “Did a doctor ever say that you had any of the
following health problems? Heart failure?” or an affirmative re-
sponse to: “Has a doctor ever told you that you had heart prob-
lems, problems with your blood circulation, or blood clots?” cou-
pled with the selection of “Heart failure or congestive heart
failure” to the follow-up question, “Please mark the conditions or
procedures below that a doctor said you had.”
* The identification of participants with cancer included an affir-
mative response to any of the following questions: “Did a doctor
ever say you had breast cancer?”, “Did a doctor ever say you had
colon, rectum, bowel, or intestinal cancer?”, “Did a doctor ever
say you had endometrial cancer (cancer of the lining of the uterus
or womb)?”, “Did a doctor ever say you had skin cancer?” (not mel-
anoma), “In the last 10 years, did a doctor ever say that you had any
other cancers?”, and “Did a doctor ever say that you had cancer, a
malignant growth, or tumor? (This does not include fibroids of the
uterus.)” coupled with, “What kind of cancer did you have?”
Overnight hospitalization was determined based on an affir-
mative answer to the following question: “Have you been hos-
pitalized overnight at any time during the past 2 years?” Body
mass index was calculated and respondents were divided into
categories based on their response (25, 25–29.9, 30–34.9, 35–
39.9, and 40).
Statistical analyses
For the cross-sectional analyses using baseline data, demographic
characteristics and baseline service use are presented. Because
the relationship at baseline between Hgb and SF-6D was not linear,
three cutpoints were chosen where the relationship appeared to
be linear (12, 12–13.9, 14 g/dl) (Fig. 1). A test of linear contrasts
was performed to compare utilities for Hgb more than 14 g/dl to
those with Hgb less than 14 g/dl for all subjects, healthy subjects,
and those with osteoarthritis, cancer, and HF.
Multiple linear regression models were used to evaluate the
independent association between Hgb level (defined by the inter-
action term of HgbHgb category) and the SF-6D, while adjusting
for selected covariates mentioned above, including sociodemo-graphic characteristics, medication use, depression, and associ-
ated disease states. Regression models were adjusted for potential
confounding of baseline socio-demographic factors, body mass
index, physical activity, depression, disability, associated disease
states, and cohort assignment using a backward selection process.
The validity of model assumptions were evaluated using analysis
of residuals. R2, Akaike information criteria, and bayesian infor-
mation criteria were used to evaluate the goodness of fit for the
model. Confounders had to change odds ratio by 10% to be used in
our final adjusted models. All P values were calculated with two-
sided significance level of 0.05.
Adjusted least-squares means were calculated based on the
regression analyses. Mean values for the SF-6D utility weights
were plotted against Hgb level for the sample as a whole as well as
separately for those with HF, cancer, osteoarthritis, or “healthy”
(not having HF, cancer, or osteoarthritis as self-identified on the
WHI instrument, and having a comorbidity index of zero as de-
fined by the WHI-modified Charlson Index) [20].
Using longitudinal data, the relationship between the change
in Hgb values and the change in SF-6D utility weights was exam-
ined. Multiple linear regression was used to evaluate the indepen-
dent association between a 2 g/dl drop in Hgb compared to no loss
and change in SF-6D, while adjusting for baseline Hgb group; body
mass index; education level; race/ethnicity; age; exercise level; de-
pression; self-reported history of diabetes, disability, any hospital-
izations duirng past 2 years, stroke/myocardial infarction, or can-
cer (if appropriate); and NSAID use. The 2 g/dl drop in Hgb was
chosen based on previous defination of clinically important blood
loss [3] and clinical trial evidence of significant difference in phys-
ical functioning [21].
Table 1 – Baseline characteristics of postmenopausal
women participants.
Variable
No. of subjects 158,257
Age (mean y  SD) 63.2  7.23
Race (%)
White 82.59
African American 8.97
Hispanic 4.01
Asian/Pacific Islander 2.59
Other 1.84
Education (%)
High school 1.66
High school 20.96
College 37.92
College 39.46
Current smoking (%) 7.00
Physical activity (mean MET h/wk  SD) 12.44  13.73
Body mass index (mean  SD) 27.97  5.93
Disabled (%) 2.06
Lupus (%) 0.43
Osteoarthritis (%) 42.16
Diabetes (%) 4.40
Liver disease (%) 2.34
Cancer (%) 9.52
Congestive heart failure (%) 1.24
Myocardial infarction or stroke (%) 3.42
Service use
Hospitalized overnight in past 2 years (%) 14.99
Nonsteroidal anti-inflammatory drug use (%) 18.55
Acetaminophen use (%) 8.50SD, standard deviation.
a559V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 5 5 – 5 6 3All data analyses were performed using SAS version 9.1.3 (2004;
SAS Institute, Inc., Cary, NC).
Results
From the 161,808 women in WHI, we excluded women with missing
or out of the physiologic range Hgb levels (n 2152), and those with
certain medical conditions that may lead to anemia unrelated to po-
tential blood loss such as sickle cell anemia or chronic kidney disease
(n  1399). This left 158,257 women to be included for the cross-
sectional analysis (Fig. 2). The baseline characteristics of the women
are presented in Table 1. The sample included in these analyses has
n average age 63 years, is mostly white (82.6%), and nearly three-
Fig. 3 – Unadjusted Short Form-6D utility weigh
Table 2 – Adjusted* average change in participants’ Short F
Participant Hemoglobin
level change
n
All eligible participants Loss 1064
No Loss 63,097
Healthy participants Loss 254
No Loss 21,230
Heart failure participants Loss 34
No Loss 724
Cancer participants Loss 164
No Loss 8414
Osteoarthritis participants Loss 511
No Loss 27,025
* Estimates adjusted as follows: all eligible, heart failure, cancer, o
education level, race/ethnicity, age, exercise level, depression, and
disability, any hospitalizations in past 2 y, stroke or heart attack, ca
baseline hemoglobin group, body mass index, education level, racein past 2 years, and nonsteroidal anti-inflammatory drug use.quarters is college educated. The most frequently reported disease
was osteoarthritis (47.2%). Just under 10% reported having had can-
cer. Fifteen percent of women have had a hospitalization during the
past year. Less than 20% use NSAIDs.
Figure 1 shows the cross-sectional relationship of covariate ad-
justed mean utility weights for the entire baseline sample, those who
were “healthy” and the women with osteoarthritis, HF, and cancer
within WHI by Hgb levels. As might be expected, those “healthy”
women without documented chronic disease had the highest levels
of utiliity across all levels of Hgb. Women with HF had the lowest
health utilities, with sequentially higher utilities for osteoarthritis,
history of cancer, and the entire cohort. In addition, for each gram of
Hgb below 14 g/dl the health utilities were lower (P 0.0001).
hemoglobin (Hgb) level at baseline and year 3.
-6D (SF-6D) response.
P loss vs.
no loss
Change in SF-6D
Mean (standard error) P (H0: x  0)
0.0001 0.0394 (0.004014) 0.0001
0.0092 (0.002745) 0.0008
0.0001 0.0158 (0.008651) 0.0687
0.0155 (0.006166) 0.0117
0.1671 0.0217 (0.022030) 0.3242
0.0041 (0.014890) 0.7812
0.0001 0.0538 (0.010340) 0.0001
0.0102 (0.007049) 0.1477
0.0001 0.0335 (0.005764) 0.0001
0.0070 (0.003830) 0.0694
rthritis: adjusted for baseline hemoglobin group, body mass index,
eported history of diabetes, rheumatoid arthritis (not on treatment),
and nonsteroidal anti-inflammatory drug use. Healthy: adjusted for
icity, age, exercise level, depression, disability, any hospitalizationsts byorm
steoa
self-r
ncer,
/ethn
t
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had valid Hgb and utility weight values at baseline and year 3
(n  68,839). Only those women with nonmissing values for the
covariates were used in the multivariate analyses (n  64,161).
Utility weights were calculated using year 3 data and compared
to baseline data. Figure 3 presents the average baseline and year 3
utility weights for year 3 and baseline by Hgb. Subjects with base-
line Hgb in the anemic range had larger declines in utility than
those with normal or high levels.
Table 2 demonstrates the adjusted mean change in SF-6D by the
Hgb change group (loss vs. no loss) for all eligible participants in the
WHI sample. Those women who lost 2 g Hgb or more between base-
line and year 3 had a statistically significant decline in SF-6D during
the 3-year period (P 0.0001). This decline in the SF-6D (0.0394) was
also clinically significant, given a MCID level of 0.025 for the SF-6D
measure [17]. A comparison of the change in SF-6D between women
who lost 2 g Hgb or more and those with no loss in Hgb level shows
the difference is statistically significant (0.0394 vs. 0.0092, P 
0.0001 ) and is also clinically meaningful.
Table 2 also shows the adjusted change in SF-6D by Hgb change
group for four separate cohorts: healthy (no self-reported disease),
Table 3 – Regression analysis of the relationship between
among all subjects.
Variable
Intercept
Hemoglobin change group Loss
No Loss
Age
Race Other
American In
Asian or Pac
Black or Afr
Hispanic/La
White (not o
Education level High scho
High school
Some colleg
College
Body mass index category 25
25–29.9
30–34.9
35–39.9
40.0
Diabetes with medications No
Yes
Disabled No
Yes
Rheumatoid arthritis without medications No
Yes
Hospitalized in past 2 y No
Yes
Exercise level (METS)
Depression score
Stroke or heart attack No
Yes
Cancer diagnosis No
Yes
Nonsteroidal anti-inflammatory drug use No
Yes
Baseline hemoglobin group 12 mg/dl
12–13.9 mg/
14.0 mg/dl
Fit statistics R2and self-reported HF, cancer, and osteoarthritis.Thelossof2g/dlHgbwasassociatedwithastatisticallysignificant (P
 0.05) as well as a clinically meaningfully decline in SF-6D in all partic-
ipants as well as in the group of participants with cancer and osteoar-
thritis, respectively (Table 2). A comparison of the change in SF-6D be-
tween those who lost 2 g/dl Hgb or more and the no loss group shows a
statistically significant difference in healthy participants (P  0.0001),
participants with osteoarthritis (P0.001), and participants with cancer
(P 0.0001) but not in participants with HF (P 0.1671).
Tables 3 and 4 show the relationship between all covariates and
he change in SF-6D among all subjects (Table 3) and in each cohort
Table 4). In addition to the Hgb loss, age and depression score are
ignificantly associated with the change in SF-6D among all study
ubjects, healthy participants, participants with osteoporosis and
articipants with cancer, but not in participants with HF.
Discussion
Based on a large population of postmenopausal women, our study
shows that lower levels of Hgb (up to 14 g/dl) are associated with
lower health utility among all participants and also in the subgroup
variates and the change in Short Form-6D response
vel Coefficient P
0.0298 0.0001
0.03017 0.0001
Reference
0.00073 0.0001
0.00507 0.1488
or Alaskan Native 0.00201 0.7587
lander 0.00211 0.3598
American 0.00321 0.0548
0.00132 0.5851
panic origin) Reference
0.005496 0.1916
0.00276 0.0135
0.00261 0.0036
Reference
0.003496 0.3728
0.008325 0.0001
0.006589 0.0001
0.003069 0.0757
Reference
0.005072 0.0267
Reference
0.00526 0.0978
Reference
0.002866 0.1288
Reference
0.00258 0.0218
Reference
0.00006 0.0268
0.07191 0.0001
0.004987 0.03
Reference
0.002389 0.0413
Reference
0.00366 0.0004
Reference
0.000244 0.897
0.00005 0.9551
Reference
0.0140all co
Le
dian
ific Is
ican-
tino
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e
dlof participants with self-report osteoarthritis, cancer, and HF. For
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561V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 5 5 – 5 6 3subjects with 2 g/dl Hgb decrease or more, there is a statistically
significant and clinically meaningful decrement in health utility
among all participants as well as in those with cancer and osteoar-
thritis, whereas the HF group had too few women with a change in
SF-6D to be significant. A comparison of change in SF-6D between
those who lost 2 g/dl Hgb and the no-change group shows a statisi-
cally significant difference in all participants. The significant differ-
ence was also observed in those with osteoarthritis and with cancer.
These findings demonstrate the statistically significant and clinically
important effect that changes in Hgb level may have on health utility
in postmenopausal women. The effect may be more important for
those with chronic medical conditions who may already be experi-
encing a lower QoL.
Findings from this study are consistent with several previous
studies that used other patient-reported QoL measures to assess the
Table 4 – Regression analysis of the relationship between
each cohort.
Healthy
Variable Level Coefficient P
Intercept 0.06147 0.0001
Hemoglobin change
group
Loss 0.03129 0.0001
No Loss Reference
Age 0.00074 0.0001
Race Other 0.00477 0.4202
American Indian or
Alaskan Native
0.02609 0.0513
Asian or Pacific
Islander
0.00079 0.8144
Black or African-
American
0.00123 0.6691
Hispanic/Latino 0.00587 0.1296
White (not of
Hispanic origin)
Reference
Education level High school 0.02472 0.0040
High school 0.00154 0.4206
Some college 0.00462 0.0018
College Reference
Body mass index
category
25 0.002034 0.7537
25–29.9 0.004742 0.1377
30–34.9 0.001521 0.6361
35–39.9 0.002996 0.3982
40.0 Reference
Diabetes with
medications
No —
Yes —
Disabled No 0.01526 0.1390
Yes Reference
Rheumatoid arthritis
without
medications
No —
Yes —
Hospitalized in past
2 y
No 0.00191 0.4309
Yes Reference
Exercise level (METS) 0.00004 0.4048
Depression score 0.09791 0.0001
Stroke or heart
attack
No —
Yes —
Cancer diagnosis No —
Yes —
Nonsteroidal anti-
inflammatory
drug use
No 0.00517 0.0158
Yes Reference
Baseline hemoglobin
group
12 mg/dl 0.000201 0.9514
12–13.9 mg/dl 0.00229 0.1233
14.0 mg/dl Reference
Fit statistics R2 0.0169potential effects associated with Hgb change in people with osteoar-thritis or cancer. In a study of relationship between Hgb in patients
with rheumatoid arthritis and physical disability assessed by a
health assessment questionnaire, Han et al. [22] found lower levels of
aseline Hgb were associated with more severe physical disability
nd improvement in Hgb level after treatment was an independent
ontributor to the improvement of physical function.
In a longitudinal analysis based on data from 14 randomized
linical trials, Strand et al. [21] found that patients with arthritis
with minimal to no change in Hgb level reported statistically
significant and clinically meaningful improvements in all eight
domains of SF-36 in both women and men. In contrast, subjects
with Hgb decreases of 2 g/dl or more did not report clinically
meaningful nor statistically significant improvements in most
domains of SF-36. A comparison of changes in SF-36 scores
demonstrated statistically significant and clinically meaningful
variates and the change in Short Form-6D response in
Arthritis Cancer Heart failure
fficient P Coefficient P Coefficient P
.0328 0.0001 0.04845 0.0013 0.04227 0.3381
.02652 0.0001 0.04364 0.0001 0.02587 0.1671
ference Reference Reference
.00073 0.0001 0.00086 0.0001 0.000234 0.6905
.00276 0.6166 0.00093 0.9266 0.00877 0.7927
.01091 0.2617 0.01958 0.2867 0.03162 0.4389
.00314 0.4592 0.0008 0.9213 0.01681 0.5991
.003675 0.1566 0.00003 0.9956 0.01419 0.2451
.001813 0.6500 0.02025 0.0095 0.006248 0.8015
ference Reference Reference
.001652 0.7829 0.01181 0.3289 0.0013 0.9533
.00259 0.1288 0.0031 0.3174 0.00515 0.6213
.00157 0.2641 0.0016 0.5180 0.00043 0.9628
ference Reference Reference
.003882 0.5673 0.004891 0.6434 0.02975 0.3506
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than 2 g/dl and those with minimal to no change in Hgb level.
In patients with cancer, anemia as a significant complication
of disease itself and cancer therapies has been found to be able to
cause fatigue, dizziness, and dyspnea that can affect health-
related QoL [23]. Potentially, therapies that result in significant
increase in Hgb level may improve cancer patients’ QoL signifi-
cantly [24,25].
This study represents the first that assesses health utility
associated with changing levels of Hgb in patients with osteo-
arthritis. In patients with cancer, health utility associated with
different levels of Hgb has been previously documented. Con-
sistent with our findings, Lloyd et al. [5] showed a decrement in
health utility scores in line with worsening anemia. Unlike the
Lloyd study that looked at a sample of patients with cancer, our
study assesses health utility based on a population of post-
menopausal women. Population-based utility measures may be
more useful for informing resource allocation and decision-
making on a societal level.
The health utility scores in our study were obtained indirectly via
a generic health-related QoL questionnaire, the SF-6D. Compared to
the health utility scores obtained though direct methods such as
standard gamble or time trade-off, the scores from the indirect meth-
ods tend to be lower and the difference can be substantial [26]. Al-
though the use of indirect methods for health utility measurement
may have implications on resource allocations, there is no univer-
sally accepted theoretical basis on whether to choose direct or indi-
rect methods [26].
The health utility estimates in our study can be used in future
economic modeling studies that evaluate cost-effectiveness of in-
terventions to mitigate blood loss. These estimates also have im-
plications for future decision making regarding medication man-
agement of patients with osteoarthritis. Our analyses suggest that
2 g/dl Hgb level decrease is associated with statistically significant
and clinically meaningful decrement in health utility in partici-
pants with osteoarthritis. Because patients with osteoarthritis fre-
quently require anti-inflammatory therapy that may lead to sig-
nificant gastrointestinal toxicity-associated blood loss, it is
important to consider this when choosing treatments for osteo-
arthritis.
This study was subject to several limitations. First, this was
an observational study in which study subjects were not ran-
domized to different therapies affecting Hgb levels and there-
fore a causal relationship cannot be inferred. Although we have
tried to adjust for various factors that may have confounded the
relationship between Hgb and health utility, it is possible that un-
measured confounders may have affected our results. Second, our
study was limited to postmenopausal women and study results can
not be generalized to younger women or to men. Third, in this study,
a difference of 0.025 in SF-6D was considered to be MCID. This cutoff
score is not universally accepted and there have been debates about
the MCID for SF-6D. Finally, the disease status in this study was ob-
tained by self-report, not confirmed by physician diagnosis.
Conclusions
This study provides estimates of health utility associated with
different levels of Hgb among all postmenopausal women and also
in those with chronic conditions, including cancer, osteoarthritis,
and HF. The estimates will be useful for future economic evalua-
tions to assess cost-effectiveness of interventions to mitigate
blood loss. This study also demonstrates significant association
between Hgb and health utility in all postmenopausal women as
well as in those with selected chronic conditions. For subjects with
a 2-g/dl Hgb decrease, there is a statistically significant and clini-
cally meaningful decrement in health utility. These findings, con-
sistent with previous studies, raise concerns about potential con-sequences associated with Hgb level decrease and indicate a need
for cost-effective treatments to mitigate blood loss.
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